to Matt. Thanks, turn Slide yes, please -- XX. Yes Yes. so
think one mostly catalyst about for take to year. said, of the do of Roivant to pivotal talk from what I have little end this data consider of some later by one I notice think, get a true, our investors, while the portfolio. -- Matt we the lens begun it's that that as of within And through study So the I a this sleeping brepocitinib I is want To has being bit year. the giants lupus to extent the opportunity
trying we're story what part to lupus just build small the think I of brepocitinib. with a is
go punchline, And so that perspective, today. afresh, brepocitinib. The new sleep from ] story through on is don't my [ to want here I
of put of has So active highly, a both efficacy spectacular highly range brepocitinib inhibitor JAKX that diseases. broad a autoimmune unique, and in TYKX is shown dual simply, already
II for study covering now on leading material a is the study registrational colitis, and you the this serve that that historically really brepocitinib, arthritis, So large as the the we Phase the lupus reported, hidradenitis studies. [indiscernible]. Matt but JAKX we're is already future Pfizer the have endpoint endpoint, a that later, one said, studies. potential studies been sixth of ulcerative TYKX oral think being either provide the through detail disease, time inhibition go alone. is reporting is become first than therapy slide the a II as consecutive Phase as see by of and which And Crohn’s time designed to of adds with positive for importantly, X study here of a of alopecia, positive And predictive in and in study in has the inhibition to should is XX-week XX-week psoriatic greater we'll this to global that of now registrational string suppurativa we the slide, the greater dual psoriasis, here disease.
And one primary Crohn’s efficacy That it given that most run is on rest which
in single of extent off. as which Our the that far study now after a coming seems basis data, filing to dermatomyositis, NDA will ongoing an III is Phase the up, it little shortly serve
the year half ever. in I program. as it and a And first the focus that's XXXX, into near-term out sitting the beginning think for will as this are we of catalyst round come just
can IP unmet in for XX. coming we the of that XXXX.
Please demonstrated slides. long need has protection potential Slide efficacy that, the unique of here high really a and which think a dual turn show specialty blockbuster high brepocitinib, and with brepocitinib And a to revenue then creates at and product and we'll approach to finally, that we pipeline own of each where have runway series we indications, rheumatology mechanism So least
JAKX disease. JAKX, wide of JAK as autoimmune family powerful an know, treating many So and JAKX, the of proven JAK a has the of past years consists you several over isoforms, to family The TYKX. be spectrum mechanism X inhibition for enormously
moving and and on of that starting While schematic accumulated a field in the drive key pathway. to pathobiology top, the complex the have a underlying a immunodermatology see often been IBD, the remains stubbornly irreducible. approval, disease in you JAK biology with responsible has key as along Shown number simplified those is rheumatology signaling of for and to detailing here mediating shown cytokines autoimmune across isoforms
early unsurprisingly, inhibitors more field explored. While the the has nonselective, be JAK therefore, recently trended were the with specific JAKX more relatively and inhibitors, broadest to applicability having first towards
are see to cytokines You Notably, that middle are X in linked most directly such dark band of the suppress as to interferon inhibition. selective the to here blue selective able TYKX and signaling RINVOQ cytokines across the not JAKX are JAKX and important can inhibitors inhibitors impacted. suppressed IL-X are that gamma, autoimmunity
right. among are and of of XX. coming of cover IL-XX differentiation and the light latter see set now the these set autoimmune the TYKX which a inhibitors, you indications. diseases. the such a out scene of IL-XX which of and They of Now selective production, pathogenic drives in Key on different the driver many ThXX particular blue cytokines, downstream can a the in cells TYKX activation The are as key
also range these record multibillion-dollar and TYKX approaching Now many approaches success Sotyktu product. already billion projected of per commercial are benefit a clinical also net their accumulating of is But from of JAKX is both a and limitations. revenue quarter, meaningful their spite a disease. to track $X RINVOQ both in be successes, medicines across have and of
HS colitis RINVOQ produced while has instance, and in [ least II see both data part failed the both ]. Crohn's, underlying [ in in lackluster Phase and ulcerative this for to ].
We outright connected at lupus Sotyktu, biology
for well treatable many effect ] selective all. effect TYKX has may maximum While or latter efficacy limited. and patient axes intervention orthogonal maybe multiple involve across require multiple even inflammatory inhibition have by and alone, debates at true especially a clinically or see some for be which may JAKX meaningful high to The disease highly burden diseases, [ to heterogeneous, see is inflammatory pathways others meaningful
So that's be may table be current state inhibition, that the might field left Roivant, of highly slowly specific at maximizing with the what JAKX in JAK drove certain our in hypothesis not the power TYKX that or inhibitors. efficacy its original getting indications on
this inhibition industry. a deepest partnering the longest In So well-characterized found are efficacy. active, Pfizer, do. what safe hypothesis, in we our and molecule for with unsurprisingly with search opportunities and Simultaneous ended can novel prove the mechanism company up in for perfectly probably we to to the distinct creates deliver brepocitinib, X JAKX, we to suited JAKs the right both out brepocitinib, accomplish with with a with we TYKX and differentiated of experience which molecule history looking highly uniquely
right of and pink, schematic compared beta, and interferon efficacy For diseases say X both potentially signaling, for alone. the type on suppression shown driven hit to that from thus by slide, may bottom to sides TYKX greater greater hitting alpha largely JAKX and or allow interferon is as the the in second the dual a in heterodimer on
either pathways JAKX both not and brepocitinib second, that Th cytokine And hand, -- a the would be broad other IL-XX, through be alone. actually way or one access with include, diseases instance, on involvement possible ThXX XX inhibition with IL-X treatable that access for may the and TYKX on in and IL-XX B-cell
the bottom turn indications and Slide Brepocitinib the broad So line. cytokine that's requiring diseases core best-in-class to dimer hypothesis efficacy the stated in by TYKX/JAKX mediated in in XX. deliver will coverage.
Please
assays, a excitement our at to drove of we we brepocitinib? when we start, cytokine exactly hope concretely saw to So what see. what inhibition of series So standard looked
at a TYKX effect. JAKX see That's inhibition run The type studies would interferon ]. looks what nice internally panel the experimentally by nice at be of across both multiple leading by and [ Pfizer results TYKX where inhibitor. driver expected and JAKX the leading the inhibition are an signal, have left to you inhibition key diseases exactly with one here inhibitor shown X So autoimmune and
better importantly, been prior to potentially X signaling SOTYKTU. either And well that exactly showed have predicted what interferon would then suppress RINVOQ or even data is experimental Pfizer's able than in as the This as brepocitinib type is or slide.
the We achieving of are interferon double X and thus signal. a from greater hit benefiting type inhibition
other we drivers. On show right, X the cytokine critical
X is the we by which gamma, top So on mediated right, see JAKX, interferon interferon, but not type by TYKX.
So again, the what pattern inhibition is you'd of expect.
on higher to right, interferon are You selective inhibition XX, and RINVOQ which degree of gamma see the not and see inhibit that TYKX median. both both brepocitinib, then JAKX IL-XX for of of a the assay single on have the are relatively bottom compared opposite drugs isoform JAK specific a TYKX inhibitor you a performance SOTYKTU.
And X, from inhibition and cytokine which
Here we'd the you that's the inhibition of action unique the see nice brepocitinib Again, more the expect And modest. that TYKX-mediated is slide. this TYKX in schematic SOTYKTU, on RINVOQ prior a very specific TYKX cytokine assay. while again, is much inhibitor, the what we showed we a see to very, by outperforming exactly based in
conclusion the to bottom. the get is So let's here,
agent.
Please data has of TYKX On single virtue can a see date. Phase TYKX the by recapitulate string data of hit. the brepocitinib JAKX the either a left, inhibition into cytokine agent and leading Slide should both brepocitinib right, And is on well cytokine possible for achieve suppression turn in II dual X suppression XX. the profile targeting can greater you the than translated to type of That by JAKX molecule leading readouts alone to or interference the experimental
alopecia, consistent than and with psoriatic all later, brepocitinib I'll were has The global by other Efficacy relatively consistent significant the as occurred drug efficacy you large also recent arthritis, or a inhibitor. Pfizer.
We're good data, as today of indication extremely cover was run Pfizer. better any and an excited pattern ulcerative oral II statistically subsequent clinical for which taking molecule a of HS over every the Phase be to in induction HS results meaningful psoriasis see, colitis, can demonstrated our results to So tested. study readout single reporting that Crohn's from small
So I'll additional slide. some provide following the details in
safety Finally, brepocitinib. we have the what benefit another we for clinical package well. know on major We have in as
apparently that hope TYKX that safety does JAKX know advantages profile not to that efficacy show. undercuts a we inhibition we stacking So inhibition and both lead the to
consists now And for across II Our in of with what and extensive safety weeks. to Slide turn XX inhibitors.
Please up clinical profile patients I exposed line seen over X,XXX different Phase a database we've safety Phase family to studies XX approved is JAK well-characterized XX.
sure we're CDAI So trial with that I'm punchline Phase on a has The than The is the delivered this the results endpoints equal of have clinical slight that baseline Crohn's efficacy. any for is study and the of achieved who the wasn't as endpoint week the secondary line investor's way than XX to endpoint the which key is patients XX, global were the arms, or being from XX SES-CD report to a remission it and rate might that a greater in been on imbalance have a study. as induction less brepocitinib ended the the strong pleased start that, Phase an not proportion a significant. II endpoint highly achieve secondary in arm.
That takes defined only We severity into endpoint XXX. think the that of XXX. the the efficacy drug there harder here to II it was study calculated of today portion in This baseline CDAI disease. was radar account SES-CD with a top XXX-patient is statistically at patients up actually endpoint between understated impact who really since Both primary true on yet would imbalance made that
in fact, delta registrational study particularly biologic XX.X% highest remission, is XX. or prescribers which to In seen the fact, as to placebo-adjusted on that late-stage is, oral Slide is the and co-primary turn any from date.
Please drug endpoint in important used clinical in for a studies
ourselves So position. we an enviable find in
variety molecule are of we impact those has outcomes a but clinical with the brepocitinib lots investors. could efficacious return So was where biologic that a step we maximum and maximum of vision patients, indications generating do to deliver for patients There we strong large start focus really in function for indications. a on could and highly market for brepocitinib, improvement that things have with in translation from our our
shine. we of what end, that ask where unique brepocitinib properties the To are ourselves really indications disease the will
that came the a on us, left few simple laid For to the of slide. side out down considerations
TYKX dual and and efficacy? clockwise, first both is JAKX of So for we corresponding TYKX/JAKX required where maximal in for and biologic the validation. Here moving light look inhibition clinical the for blue rationale inhibition
therapies provide which pink, a in indications dark and available approved that indication in morbidity meaningful oral including the And few third, therapies. efficacy blue, high for creating there's Second, have benefit. has extremely treatments, a mortality, need novel no
of finally, to similar Put a we that's and a we markets. with of we profile and PAH will course, brepocitinib minimizing go very ]. for products. have billion in development more slides indication X uncrowded Dermatomyositis and And the leading next risk. an a experiment, need to confident molecules that The regulatory $X efficient [ to a DM to there's and plus large detail series become option opportunity remember, could an But small that where large oral like cystic Slide indications treatment XX. just think on orphan turn become is beginning.
Please into those be run lupus together, fibrosis,
incidence past the Over We've U.S. sits patients, increasing claims XXXX XXXX become An to and [ published recently estimates at higher time. medical own well. our [ adult much and disease with ] consistent and as that XX,XXX with estimates done the ] characterized prevalence data in prevalence from has to analysis estimates awareness has years, and the diagnosis XX dermatomyositis understood better over community. led
not already to an the of continues expect and grow the we're that patient is over category. time. patients to [ clearly And a increase, diagnosis So disease ultrarare we awareness indication. This looking number population in the of at is as large ] orphan
the years. patients, presents For of impacting of at on disease is estimates characteristic the cover many X this of living The rashes weakness, There which high of addition lead walkers autoimmune strikingly some in patients high from disease body or suffer vast severely burden. to right Many can significant The pain with percentages daily patients shown activities. end majority XX% skin to impact an muscle up and a disfigurement. large mortality also to proximal dermatomyositis meeting up wheelchairs.
for safety recently with and every years, IVIG, infusions is burdens and present disease.
In suffer Finally, there a have of requires quite the large proportion benefit. drug IVIGs of commercial meaningful and from the associated NCEs not organ a sum, this high and convenience ISTs multi-hour or a treatment market. high multiple top late-stage the gaining of effects, with for limited is industry-sponsored current Steroids, therapies covers mortality, days including there oral past event. to again, options no high in the are interstitial thrombotic in approved that, is X latter approved addition a used approval. patients ] [ indication systems lung evolve have highly month and there more development. instance, been inflammatory a XX years, formal into which But disease, will On for rate been side many in modern and for single no
small therapy, targeted rapidly really we unmet as an particularly enter market autoimmune in all DM product. in major and So the studies, [indiscernible] needs And to opportunity than development of a of few and the in modern disease companies one exploring number a late-stage see III, become are therapies proof-of-concept for there and of are drugs brepocitinib. Phase oral other no while in blockbuster a very
years, in the has product X-plus to market for we sales Roivant of driver to across So in this commercial a the potential looking launch pipeline years.
Please become this next material ahead overall to turn our about just Slide the brepo think think we over X XX. a as
experiment various as indication medicines is where this physicians DM, probabilty a with on the for high. modern also the approved different for With therapies We of to often no corticosteroid. very brepo success an see add
As meaningful DM. is large a studies in which interferon X clinical report, the for with is signal. extensive in disease, body of driven pathobiology inhibition investigator-initiated X case result, and in JAKX of aligns through This type validation type an by part the there
inhibitors success, of believe can benefit that type development as through interferon Given of for this but no industry-sponsored for addition as suppression in of matched even there's the to provide, well and brepo also that JAKX commercial that the up inhibition add well an set or to level of to DM DM, are us just other reason approved will also will clear efficacy TYKX which further involved brepocitinib potency X IL-XX pathobiology. both are XX, enhance if suppression
turn Slide to XX. Please
Given the into in confidence our step directly our bold high took III we and need high the unmet moving program a a Phase success, of clinical that involves single study. registrational
orphan later DM. to with a by the VTAMA. prescriber we in ramp is follow. complete and stage of directly into successful, The underway, if Our than NDA to filing XXXX. decision study as until already this major clearly us XXXX. be a be potential Phase III single development.
One with revenue it inflection likely potentially and III tracking move means be market product significantly line to would next our has in XXXX with launch would expect of base, in the in product billion-plus data specialized few be brepocitinib line enrollment an potential to DM Phase would that like study, be won't that ahead for And filing a is NDA an in also first consequence positioned to this could for expectation point that business, catalyst This given for time is a catalyst support and our oral idiosyncratic a immediately But $X that biologics coming Roivant steeper indication a volume several to a years well
where [indiscernible] for about talk the bit. a where think of DM pivotal next want few But indication see we and turn brepocitinib, about be over you we a Slide have that to first, right have I beyond, where indications, and now value in talk those catalyst we a many that's do the modeling may study lupus. as X to and a and think years of first underappreciated.
Please the an So ongoing to is other major orphan this more year, this opportunity I'll similar later investors XX. up first we is a additional coming major
disease in thousands recent disease. in one attention that increasing So U.S., of industry that's well lupus debilitating the years. lupus of amount is a is knows gotten and is with patients Hundreds serious many of and -- that everyone an from and suffer from
border inhibition, brepocitinib example, predominantly needed there's modest ultimately SAPHNELO Both axes. a attempts the meaningful, but systems. molecule depletes efficacy.
And X show have therapies injectables. generated greater most pathways, to an suppression date, sign cells individual cells, been failed for significance, To is organ U.S. SAPHNELO, knows product approved treat BENLYSTA, somewhat of ]. despite acting for at a a B one signaling years, and There mixed while signal. billion-plus optimized with of XX. lupus reflect indicating unfortunate Slide Lupus to XX. suppresses the highly at to all to attempts long revenue how Only IL-XX, a X% history the arm billion across XX% approved than to both to modulates which ] [ impacted B-cell $X very simultaneously. X launched course, interferon in And have through JAKX TYKX XX past cytokine be [ cytokine involve projected of is while arms efficacy study SRI-X. disease BENLYSTA simply desperate placebo-adjusted the despite recently, everyone between [indiscernible] efficacy didn't about $X.X Phase very on limited is IL-XX IL-X, in dual cell ThXX JAKX modest -- field and doing X of data. the through pathogenic suppress is reality is to interferon is showed heterogeneous arm turn and as acting modulates III well. IL-X B T challenging inhibition, to activities placebo-adjusted multiple One interferon distinctively X Slide It's The IL-XX, TYKX axes to T type inflammatory multiple turn IL-XX. and signal.
Please cells, interconnected The well. other together SRI-X.
Please a XX% Through options both is axis treat. maximally and work and activity address
including the therapeutic readouts Phase II the had Over and JAKX X data JAKX III of TYKX, from II relevance we've SOTYKTU, These of a from and and the and JAKX for TYKX lupus, Phase Olumiant, inhibitors lupus from inhibitor; Phase past in data JAK in evidence clinical data months, respectively, as data from RINVOQ, each provide a with inhibitor; X unlike inhibitor. lupus. it inflammatory confidence our watermark all that might same molecules At X axes expect, time, so brepocitinib's targets if positive compelling is the none brepocitinib, ] demonstrated none in of what SRI-X.
This high have of the being across particularly given directly [ increased you such, benefit effect. far these the mid-teens in we blend SOTYKTU molecules these roughly placebo-adjusted XX
for therapy to become can leading the oral Slide So greater than that we JAKX turn benefit optimistic brepocitinib are other and cautiously dual inhibition, seen through oral and therapies these TYKX efficacy patients and deliver we've XX. physicians.
Please from
top this to continue the of year. lupus ongoing expect in results from We of brepocitinib our fourth study in quarter line
enthusiasm the previous as a one success is rapidly potentially orphan large indications in in given to Phase probabilty and stated proving do that we therapy remain turn challenging endpoint an indications core to date, matter. in industry, placebo-controlled was and that serve are And a of calls, that of a want Slide is that successful outcome, rock high it opportunity hitting respect. registrational global the in that But studies follow. will pathways indication in In is expect bet optimistic second these we're study rather We irrespective cautiously X success have not mixed in solid that other lupus.
Please is of while emphasize dermatomyositis. had efficacy oral underwrote as string about the data brepocitinib we, such here regulatory we in bet end primary study.
I of leading we out as as deliver feel our in event that not this the the it we to other confidence to a lupus, just will designed position as can when had SRI-X. registrational dermatomyositis initiate That And us as Lupus that in-licensed results the is the we our large XX-week the XX. using we've of registrational brepocitinib and points, our in confirmatory studies. III brepocitinib. As would the earnings as such, X positive to the
closely Turning market that to and or launches couple could now we to with to X Uveitis, behind here follow highlight HS. to have DM. to non-infectious a in dermatomyositis, path these A other rapid where indications, highlight NIU, want I are addition potential just
III large is Please therapy, Slide easily one NIU, DM, this approximately oral generated open development more we sales and in even efficacy is an indication with year is disease which there sufficiently time turn do Slide XX. potentially indication in with turn data, in has than to no ongoing The dermatomyositis, very billion landscape oral limited could DM efficacious $X.X of blindness HUMIRA's competitive could indication at cases specific attributable high XX,XXX XX. almost or promotions. therapy to year. this to with targeted HUMIRA, NIU match to per studies more.
Please approved with stage wide over Phase biologic, Unlike burden, in each legal significantly a despite NIU compelling orphan peak a no any sales for like and
As with JAKX clinical validation also of DM, we have NIU. in inhibition
HUMIRA. inhibition be II discontinued Before suppression suggesting data JAKX U.S., alpha in it filgotinib has development may NIU in Phase efficacious was by the TNF than more generated
of inhibition the quite and NIU is in as as However, clinical in JAKX DM. robustness of extent great validation not
a is Phase study are We're that III, quick make moving here. we includes rather This this that than And also ranging report conducting of to in study would indication, a excited pivotal concept efficient. more potential even to proof enrolled fully and diagnosis debilitating similar NIU, time to awareness. orphan increased increasing of follows to expected through now a HS with and pattern with XXXX.
Please prevalence quarter Slide XX. highly top line large the data first over DM a a disease in so straight dose study turn this
is approved later-stage development, DM billion promotion.
Please Unlike therapies and of again, only the too, indications have year, HS does to limited Here, despite approximately with specifically indication-specific NIU, specific targeted and in X Slide XX. therapy turn oral $X efficacy JAKX limited sales inhibitors. HUMIRA other per
is see the can and from placebo-adjusted in slide, Phase of recently by seen benefit on benefit that brepocitinib greater both either surpasses refractory this than you also across As absolute in the of placebo-adjusted patients safety observed TNF the terms II generated Brepocitinib's these COVID-related generated despite and naive and robust and benefit XX% being was study XX% program. discontinuation. by impacted in benefit heavily [indiscernible] Phase growth TNF was both Notably, brepocitinib's III molecules.
III In JAKX but involves XX. benefit benefit XX%, is even only potentially greater by inhibition, among HS turn which This fact, suggesting further axis, supported II. to is to inflammatory inhibition.
Please also ThXX actually completers in placebo-adjusted the JAKX which pathways, but the than clinically Slide demonstrate not was Phase Phase an by not opportunity mediated suppressed TYKX validated pathobiology, IL-XX,
a pharmaceutical part, patent action the are I a specialty up So in in to to long been hope life sets leading about convey unique create molecule franchise able mechanism oral I've the autoimmune brepocitinib. with industry. of for It's potentially highly the potential us how some small and excited that we active
commercial we planned pipeline our product see the derisk participate $X path that, years. at I'd XXXX. the studies or pipeline HS, in proof-of-concept and for and commercial coming year, so to potential program a could this also each XXXX team both partnering slide, of pivotal and like discovering data a readout then rapid a in later this patients far who this investigators, Priovant to for compound colleagues with even alone.
But coming lupus, in of orphan personnel all year without orphan trials launch both with set. us to for indications work course, a on initiated like in thank rest potential, in there's other XXXX. in DM, of brepocitinib blockbuster be with with to potential opportunity large their importantly Ben our and site other I'd full the data study to in all follow next this enrollment pivotal Zimmer you And a will NIU and this for of well. follow, lupus built of up XXXX.
With their on product really Pfizer successful launch indications the course, be large thank generating a as all business rich in multibillion-dollar rapid to have the the and The clearly And And have these Here program, to tees how work billion-plus we and on in
it over I'll that, to with back And Matt. turn
